Overview

PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Status:
Not yet recruiting

Trial end date:
2023-08-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to explore the efficacy and safety of compare the efficacy and safety of PD-1 inhibitor and chemotherapy（treatment group） with chemoradiotherapy（control group） in neoadjuvant treatment of resectable thoracic esophageal squamous cell carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Fujian Cancer Hospital

Collaborator:

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Treatments:

Albumin-Bound Paclitaxel
Immune Checkpoint Inhibitors
Paclitaxel